From cutting-edge aortic interventions to consensus on revascularisation strategies in the peripheral arteries, the 2023 edition of the Charing Cross (CX) Symposium comes at a crucial time in the calendar for the cardiac, aortic, vascular and endovascular communities.
The three-day CX Symposium—taking place 25–27 April—returns to the Hilton London Metropole in central London for its second consecutive year, with attendees also tuning in virtually from across the globe. It is anticipated that the event will welcome more than 2,500 in-person attendees, with over 1,000 remote participants.
CX continues its three-year cycle of raising vascular and endovascular controversies in order to challenge the available evidence and to be able to reach a consensus after discussion with an expert audience. Sessions will explore routes to consensus in all vascular domains, spanning aortic, peripheral, venous, acute stroke and vascular access, punctuated by CX debates, live and edited cases and workshop demonstrations.
Running over the three days, the comprehensive aortic programme opens with aortic techniques and technologies on day one, followed by a full day focused on the abdominal and juxtarenal aorta, and finishing with debate centring on the thoracic aorta.
The sessions bring together world-leading experts in management and treatment of aortic disease from the cardiovascular, vascular and endovascular worlds, with faculty including Gustavo Oderich (University of Texas Health Science Center at Houston, Houston, USA), Joseph Bavaria (University of Pennsylvania, Philadelphia, USA), Maximilian Pichlmaier (Ludwig Maximilian University Munich, Munich, Germany) and Marco Virgilio Usai (St Franziskus-Hospital Muenster, Muenster, Germany).
Commenting ahead of the symposium, Oderich, a member of the CX Aortic Executive Board, said: “We are all excited to see the latest advances in the arch and thoracoabdominal aorta, and for me personally, to learn from colleagues in Europe and the UK on what is going on there, and what I should change in my techniques.”
Highlights from day one include insights into advances in both open and endovascular thoracic aortic aneurysm (TAA) repair, options for the treatment of complex aortic pathologies, and a focus on the aortic dissection toolkit.
A podium first presentation from Kevin Mani (Uppsala University, Uppsala, Sweden) is among the highlights from the abdominal aortic session at the start of day two, exploring the benefits of statin treatment after aortic repair. The following juxtarenal aortic consensus update session includes discussion on the impact of the ETTAA (effective treatments for thoracic aortic aneurysms) and UK-COMPASS (UK complex aneurysm) studies results with reference to National Institute for Health and Care Excellence (NICE) guidelines.
Thursday’s thoracic aortic consensus sessions close off the aortic programme with a debate on the conservative management of aortic intramural haematoma, featuring Michel Makaroun (University of Pittsburgh, Pittsburgh, USA) and Jean Panneton (Eastern Virginia Medical School, Norfolk, USA).
Treatment strategies for patients with chronic limb-threatening ischaemia (CLTI) have been firmly in the spotlight following the release of the first results from BEST-CLI in November 2022. CX will provide a platform to move the conversation forward, with first-to-podium results of the BASIL 2 randomised trial—comparing a ‘vein bypass first’ or a ‘best endovascular first’ revascularisation strategy—forming the centrepiece of a peripheral trial consensus update, taking place on the first day of the CX symposium.
During the session, BASIL 2 chief investigator Andrew Bradbury (University of Birmingham, Birmingham, UK) will deliver the first results from the trial, in a session that also sees participation from BEST-CLI investigators Matthew Menard (Brigham and Women’s Hospital, Boston, USA)—providing an update on the trial—and Alik Farber (Boston Medical Center, Boston, USA), presenting BEST-CLI quality-of-life data.